(2S,3S)-3-(6-Methoxy-1,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2S,3S)-3-(6-Methoxy-1,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine
• 英文别名: (2S,3S)-6-Methoxy-1,3,3-trimethyl-5-[(2-phenyl-piperidin-3-ylamino)-methyl]-1,3-dihydro-indol-2-one；6-methoxy-1,3,3-trimethyl-5-[[[(2S,3S)-2-phenylpiperidin-3-yl]amino]methyl]indol-2-one
• 化学式: C₂₄H₃₁N₃O₂
• 分子量: 393.529
• InChiKey: HLAFYQGUBXOXEV-UGKGYDQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2S,3S)-3-(6-Methoxy-1,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine 在 盐酸 作用下， 以 甲醇 为溶剂， 以70.4%的产率得到(2S,3S)-3-(6-methoxy-1,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine dihydrochloride
  参考文献：
  名称：

  SUBSTITUTED BENZOLACTAM COMPOUNDS

  摘要：

  公开号：

  EP1175417B1
• 作为产物：
  描述：

  (2S,3S)-1-tert-butoxycarbonyl-3-(6-methoxy-1,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine 在 盐酸 、 水 作用下， 以 乙酸乙酯 为溶剂， 反应 0.75h， 以93.6%的产率得到(2S,3S)-3-(6-Methoxy-1,3,3-trimethyloxindol-5-yl)methylamino-2-phenylpiperidine
  参考文献：
  名称：

  SUBSTITUTED BENZOLACTAM COMPOUNDS

  摘要：

  公开号：

  EP1175417B1

文献信息

• Substituted benzolactam compounds
  申请人：——

  公开号：US20030105124A1

  公开（公告）日：2003-06-05

  This invention relates to compounds of the general formula (1): 1 or a pharmaceutically acceptable salt thereof, W, T, Y, X, Q, R 1 , R 2 , and R 3 are defined herein. This invention also relates to compounds of the formula I, depicted above, wherein Y is —NH—; T is (2S,3S)-2-phenylpiperidin-3-yl, where the phenyl group of said (2S, 3S)-2-phenylpiperidine-3-yl may optionally be substituted with fluoro; Q is oxygen and is double bonded to the carbon atom to which it is attached, X is methoxy or ethoxy, R 1 is hydrogen, methyl or halo-C 1 -C 2 alkyl, W is methylene, ethylene or vinylene; R 2 and R 3 are independently hydrogen or methyl, or one of R 2 or R 3 may be hydroxy, when W is ethylene, R 2 and R 3 are both methyl, when W is methylene, and R 2 and R 3 are both hydrogen, when W is vinylene. The invention is further directed to methods of treating various CNS and other disorders using said compounds and pharmaceutical compositions thereof.

  这项发明涉及通式（1）：1的化合物或其药学上可接受的盐，其中W、T、Y、X、Q、R1、R2和R3的定义如本文所述。本发明还涉及上述示出的通式I的化合物，其中Y为—NH—；T为（2S,3S）-2-苯基哌啶-3-基，其中所述（2S,3S）-2-苯基哌啶-3-基的苯基可以选择地被氟取代；Q为氧并与其连接的碳原子双键结合，X为甲氧基或乙氧基，R1为氢、甲基或卤代-C1-C2烷基，W为亚甲基、乙烯基或乙烯基；R2和R3独立地为氢或甲基，或R2或R3中的一个可能为羟基，当W为乙烯基时，R2和R3均为甲基，当W为亚甲基时，R2和R3均为氢，当W为乙烯基时，R2和R3均为氢。该发明进一步涉及使用上述化合物及其药物组成物治疗各种中枢神经系统和其他疾病的方法。
• Benzoamide piperidine containing compounds and related compounds
  申请人：——

  公开号：US20030087925A1

  公开（公告）日：2003-05-08

  The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

  本发明涉及某些含有苯甲酰胺哌啶类化合物和相关化合物，其表现为NK-1受体拮抗剂（例如，物质P受体拮抗剂），以及含有它们的制药组合物，并且它们在治疗和预防中枢神经系统疾病、炎症性疾病、心血管疾病、眼科疾病、胃肠疾病、幽门螺杆菌引起的疾病、免疫系统疾病、尿失禁、疼痛、偏头痛、呕吐、血管生成和其他疾病中的使用。
• Combination treatment for depression and anxiety
  申请人：——

  公开号：US20020049211A1

  公开（公告）日：2002-04-25

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a 5HT1D receptor antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a 5HT 1D receptor antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）的抑郁症或焦虑症的方法，通过给哺乳动物（例如人类）口服中枢神经系统穿透性NK-1受体拮抗剂（例如物质P受体拮抗剂）与5HT1D受体拮抗剂的组合。此外，本发明还涉及含有药学可接受载体、中枢神经系统穿透性NK-1受体拮抗剂和5HT1D受体拮抗剂的制药组合物。
• NK-1 receptor antagonists and eletriptan for the treatment of migraine
  申请人：Pfizer Products Inc.

  公开号：EP1095655A2

  公开（公告）日：2001-05-02

  The present invention relates to a method of treating or preventing migraine in a mammal, including a human, by administering to the mammal eletriptan or a pharmaceutically acceptable salt of eletriptan and an NK-1 receptor antagonist (e.g., a substance P receptor antagonist). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, eletriptan or a pharmaceutically acceptable salt of eletriptan and an NK-1 receptor antagonist.

  本发明涉及一种治疗或预防哺乳动物（包括人类）偏头痛的方法，其方法是向哺乳动物施用依立普坦或依立普坦的药学上可接受的盐和NK-1受体拮抗剂（如P物质受体拮抗剂）。它还涉及含有药学上可接受的载体、依利普坦或依利普坦的药学上可接受的盐和 NK-1 受体拮抗剂的药物组合物。
• Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
  申请人：Pfizer Products Inc.

  公开号：EP1099446A2

  公开（公告）日：2001-05-16

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an anxiolytic agent or antidepressant.

  本发明涉及一种治疗哺乳动物（包括人类）抑郁或焦虑的方法，其方法是向哺乳动物施用中枢神经系统穿透性NK-1受体拮抗剂（如P物质受体拮抗剂）与抗抑郁剂或抗焦虑剂联合使用。它还涉及含有药学上可接受的载体、中枢神经系统穿透性 NK-1 受体拮抗剂和抗焦虑剂或抗抑郁剂的药物组合物。